KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Operations: 2020-2025

Historic Cash from Operations for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$117.4 million.

  • Recursion Pharmaceuticals' Cash from Operations fell 98.16% to -$117.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$441.2 million, marking a year-over-year decrease of 38.81%. This contributed to the annual value of -$359.2 million for FY2024, which is 24.81% down from last year.
  • Recursion Pharmaceuticals' Cash from Operations amounted to -$117.4 million in Q3 2025, which was down 53.58% from -$76.4 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Cash from Operations registered a high of $77.4 million during Q1 2022, and its lowest value of -$132.0 million during Q1 2025.
  • In the last 3 years, Recursion Pharmaceuticals' Cash from Operations had a median value of -$76.4 million in 2025 and averaged -$88.4 million.
  • In the last 5 years, Recursion Pharmaceuticals' Cash from Operations plummeted by 813.38% in 2021 and then skyrocketed by 351.63% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Cash from Operations (Quarterly) stood at -$61.2 million in 2021, then grew by 26.83% to -$44.7 million in 2022, then tumbled by 65.54% to -$74.1 million in 2023, then plummeted by 55.82% to -$115.4 million in 2024, then plummeted by 98.16% to -$117.4 million in 2025.
  • Its last three reported values are -$117.4 million in Q3 2025, -$76.4 million for Q2 2025, and -$132.0 million during Q1 2025.